NADH-IN-3

• Description:

  NADH-IN-3 (Compound C4-1) is a NADH inhibitor with a MIC of 4 μg/mL (13.042 μM) for type II NADH dehydrogenase of Mycobacterium tuberculosis (Mtb) . NADH-IN-3 significantly interrupts ATP synthesis, shows potent inhibitory effects against mono (Rifampicin (HY-B0272) and Isoniazid (HY-B0329) ) and multi drug-resistant (Mtb) strains and an anti-bactericidal activity against HepG2 cells with low cytotoxicity (SI: 16.52) [1].

• UNSPSC:

  12352005

• Target:

  Endogenous Metabolite

• Related Pathways:

  Metabolic Enzyme/Protease

• Field of Research:

  Infection; Metabolic Disease

• Smiles:

  CC(C1=CC2=C(N=C(S2)SCC(NC3CC3)=O)C=C1)C

• Molecular Formula:

  C15H18N2OS2

• Molecular Weight:

  306.45

• References & Citations:

  [1]Saha P, et al. Targeting drug-resistant tuberculosis: Thioacetamide-substituted benzothiazoles as bactericidal agents inhibiting type II NADH dehydrogenase. Bioorg Chem. 2025 Jul 3;163:108718.

• Shipping Conditions:

  Room temperature

• Scientific Category:

  Reference compound1

• Clinical Information:

  No Development Reported

• Isoform:

  Microbial Metabolite